Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.
Lava Therapeutics has raised €70M across 1 funding round from 2 investors, most recently a Series C round in Sep 2020. Based in Utrecht, Netherlands; founded 2016; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-09-17 | Series C |
| €70M |
| Novo Ventures,Sanofi Ventures |
| View deal → |
